Biotech stocks are entering September 2026 with a more constructive market narrative than they had during the post-pandemic slump. Investors are again rewarding clinical innovation, meaningful data and dealmaking, but the market is also placing greater emphasis on commercial revenue and catalysts that are closer to realization. That combination creates a wider opportunity set: established biotechnology companies can offer earnings support, while development-stage businesses retain significant upside if their programs produce compelling results or attract strategic interest.
Several structural forces are supporting the sector. Lower rates can improve the appeal of long-duration biotechnology assets, while large pharmaceutical companies facing future patent cliffs have more incentive to acquire differentiated pipeline programs. A steadier FDA backdrop and a reopening IPO window are also supporting risk appetite. The most important areas to understand include small- and mid-cap developers exposed to potential M&A, obesity and metabolic disease adjacencies, platform tools, royalty structures and commercial-stage specialty medicines. Early gene therapy and preclinical discovery remain more funding-sensitive. Eli Lilly's announced purchase of Ajax Therapeutics has further underscored the appetite for pipeline assets.
This seven-stock countdown spans rare-disease developers, CNS specialists, commercial-stage biotechnology leaders and large-cap companies with broad therapeutic portfolios. The ranking considers depth of exposure to the biotech theme first, then business fundamentals such as profitability, growth, valuation and earnings execution. The picks appear in countdown order, beginning with number seven and moving toward the best-ranked stock at number one.
To build the list, we screened US-listed biotechnology companies with market capitalizations above $500 million and filtered for direct exposure to drug discovery, development, commercialization or biotech-enabled therapeutic platforms. We then considered the breadth and maturity of each company's pipeline, commercial revenue base, profitability, growth profile, valuation and recent earnings performance. Depth of thematic exposure determines the initial order, while fundamentals help separate companies with operating support from more speculative names. This is a countdown: the best pick is reserved for number one at the end.
What they do. The company develops and commercializes medicines for hereditary angioedema and other rare diseases. Its commercial base includes ORLADEYO, an oral serine protease inhibitor for HAE, and RAPIVAB, RAPIACTA and PERAMIFLU for influenza, while its pipeline includes Phase 3 navenibart and earlier programs such as BCX17725, avoralstat and STAR-0310. The combination of a marketed rare-disease medicine and internally developed candidates gives BioCryst a more tangible commercial position than a purely preclinical biotech.
Why it fits. BioCryst is a direct biotechnology exposure through its rare-disease focus, commercial HAE franchise and clinical programs targeting additional conditions. Navenibart's Phase 3 status provides a more advanced catalyst than the company's Phase 1 programs, while ORLADEYO gives investors exposure to a product already being commercialized rather than only laboratory or clinical optionality.
Numbers that matter. Revenue growth was 33.6% year over year, and the company reported a 77.4% gross margin. The operating margin was 45.12%, but the net margin was negative 40.9%, with trailing EPS of negative $1.40. BioCryst is not profitable on the supplied figures, although the forward P/E of 13.9665 is more moderate than the valuation of many development-stage biotechs if the projected next-year EPS of $0.94 is achieved.
Recent momentum. BioCryst's August 5 quarter produced EPS of $0.30 versus an estimate of $0.14, a 114.3% surprise, and the earnings history shows a 6/7 beat rate. Analysts list five buys and one hold, with an average target of $20.6364. The main limitation is that the strong recent earnings record has not yet translated into consistent bottom-line profitability, keeping the stock more dependent on product growth and pipeline progress.
What they do. Axsome develops and commercializes therapies for central nervous system disorders. Its commercial portfolio includes Auvelity for major depressive disorder, Sunosi for excessive daytime sleepiness and Symbravo for acute migraine, while its pipeline includes AXS-05, AXS-12, AXS-14 and additional solriamfetol development programs. That commercial portfolio and CNS specialization provide a defined route to revenue, while the late-stage and completed clinical programs preserve additional pipeline leverage.
Why it fits. Axsome offers direct exposure to biotechnology through novel CNS medicines and a pipeline aimed at depression, Alzheimer's disease agitation, narcolepsy, fibromyalgia, smoking cessation and other conditions. Its combination of marketed therapies and clinical-stage candidates fits the market's preference for companies that can pair innovation with nearer-term commercial evidence.
Numbers that matter. Revenue grew 45.5% year over year, and the gross margin was 93.2%, reflecting the economics of a branded pharmaceutical portfolio. The operating margin was negative 23.42% and the net margin was negative 24.68%, with trailing EPS of negative $3.75. The forward P/E of 36.63 is demanding, but the next-year EPS estimate of $5.034 points to a significant expected improvement if commercialization and pipeline execution continue.
Recent momentum. The latest reported quarter, dated August 10, showed EPS of negative $0.99 against an estimate of negative $0.99, while the May quarter missed by 46.5%. The earnings history records a 3/7 beat rate, so the recent operating story is less consistent than the analyst enthusiasm suggests. Still, five analysts rate the stock Buy with no listed holds or sells, and the average target is $285.4195, making execution on the commercial portfolio and pipeline especially important.
What they do. Kiniksa develops and commercializes therapies for autoinflammatory and cardiovascular diseases. Its principal commercial product is ARCALYST, an interleukin-1 cytokine trap for recurrent pericarditis and cardiac sarcoidosis, while KPL-387 is in Phase 2/3 development for recurrent pericarditis and KPL-116 remains preclinical. The company is therefore built around a focused specialty-medicine franchise rather than a broad collection of unrelated early programs.
Why it fits. Kiniksa's biotech exposure is concentrated in immunology and rare or underserved inflammatory conditions, with ARCALYST providing commercial validation and KPL-387 supplying clinical-stage optionality. The recurrent-pericarditis focus also gives the company a clear therapeutic identity, although that concentration means product and indication execution matter more than they would for a diversified biotechnology platform.
Numbers that matter. Kiniksa posted 55.4% year-over-year revenue growth and 30.4% earnings growth. It is profitable, with a 54.5% gross margin, 11.16% operating margin and 9.59% net margin. The trailing P/E was 77.4742 and the forward P/E was 59.8802, so the market is assigning a substantial premium to the company's growth and pipeline prospects. EPS was $0.97 over the trailing period, with a next-year estimate of $1.6175.
Recent momentum. The July 28 quarter delivered EPS of $0.30, exactly matching the $0.30 estimate, while the April quarter beat by 68.8%. The reported earnings beat rate is only 1/7, highlighting a history of estimates being set above actual results despite the latest revenue and earnings growth. Two analysts rate the stock Buy, with an average target of $98, but the elevated valuation leaves less room for disappointment if ARCALYST growth or KPL-387 development weakens.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
What they do. Vertex develops, manufactures and commercializes transformative medicines for serious diseases, with an established specialty portfolio in cystic fibrosis and newer products for sickle cell disease, transfusion-dependent beta thalassemia and acute pain. Its marketed products include the TRIKAFTA/KAFTRIO and ALYFTREK CF franchises, CASGEVY and JOURNAVX, while programs such as VX-522, inaxaplin and VX-264 extend the pipeline into mRNA, kidney disease and type 1 diabetes. This breadth gives Vertex one of the deeper commercial and clinical platforms in biotechnology.
Why it fits. Vertex is a direct fit for the theme because it combines a large commercial CF franchise with cell therapy, gene-editing exposure through CASGEVY and multiple next-generation development programs. The company also has a strategic collaboration to research, develop, manufacture and commercialize multispecific T-cell engagers for autoimmune diseases, adding platform depth beyond its current products.
Numbers that matter. Revenue grew 12.5% year over year and earnings grew 8%. Vertex reported a 55.0% gross margin, 38.06% operating margin and 35.0% net margin, supported by trailing EPS of $17.03. The trailing P/E was 30.219 and the forward P/E was 24.2718, a meaningful premium to slower-growth pharmaceutical businesses but more defensible given the company's profitability, commercial scale and pipeline. Next-year EPS is estimated at $20.133.
Recent momentum. Vertex reported August 3 EPS of $4.20 versus an estimate of $4.15, a 1.2% beat, and its earnings history shows a 4/7 beat rate. Analyst coverage includes four Buys, 14 Holds and one Sell, producing a Hold consensus and an average target of $569.1852. The balanced view reflects a high-quality commercial franchise alongside questions about valuation, growth durability and how quickly newer programs can add to the established CF business.
What they do. Regeneron discovers, develops, manufactures and commercializes medicines across eye disease, allergic and inflammatory conditions, cardiovascular and metabolic disease, neurology, rare disease and cancer. Its commercial portfolio includes EYLEA, Dupixent, Libtayo, Praluent and Kevzara, while its collaborations cover RNA interference, in vivo CRISPR gene editing, dual GLP-1/GIP development, radiopharmaceuticals and conditionally activated cancer therapies. This combination of commercial products and partnered innovation gives Regeneron unusually broad biotechnology exposure.
Why it fits. Regeneron sits at the intersection of the theme's strongest segments: profitable commercial biotechnology, large therapeutic franchises and a pipeline supported by platform collaborations. Its work with Alnylam on RNAi, Intellia on CRISPR/Cas9 and Hansoh on a dual GLP-1/GIP program gives investors exposure to several areas attracting capital and strategic interest without relying solely on preclinical discovery.
Numbers that matter. Revenue grew 16.7% year over year, while earnings growth was negative 4.5%. Regeneron nonetheless generated a 44.5% gross margin, 33.11% operating margin and 27.87% net margin, with trailing EPS of $39.40. The trailing P/E was 19.6475 and the forward P/E was 14.3678, a relatively restrained valuation for a profitable biotechnology company with $15.5 billion of revenue and $4.7 billion of EBITDA. Next-year EPS is estimated at $50.3847.
Recent momentum. The July 30 quarter produced EPS of $12.53 against an $8.00 estimate, a 56.6% surprise, and Regeneron has beaten estimates in six of the past seven reported quarters. Five analysts rate the stock Buy, five rate it Hold and one rates it Sell; the resulting consensus is Buy with an average target of $849.3174. The key tension is that earnings growth was negative 4.5%, so future returns will depend on sustaining product demand and converting pipeline breadth into durable growth.
Pick #2Premium members only
Premium members see this pick's full breakdown — investment thesis, key financial metrics, recent earnings execution, and analyst consensus.
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
This monthly screen covers US-listed companies classified within biotechnology or with substantial biotechnology exposure and market capitalizations above $500 million. The ranking starts with depth of thematic exposure: direct involvement in drug discovery, development, commercialization, rare disease, cell therapy, gene editing or related platforms receives priority. Business fundamentals then refine the order, including revenue growth, margins, earnings trajectory, valuation, analyst expectations and recent earnings surprises. The article uses primary-source financial data and composite metrics available at the refresh date. Because biotechnology fundamentals and clinical catalysts can change quickly, the list is refreshed monthly rather than treated as a permanent ranking.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
